MADISON HEIGHTS, Mich., April 27 /PRNewswire-FirstCall/ -- InfuSystem (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced that it has hired Bryan Russo as Chief Commercial Officer of the company. In this newly formed position, Mr. Russo will be responsible for overseeing sales and expanding the company's market presence.
Prior to joining InfuSystem, Mr. Russo was Regional Vice President of Sales at Gentiva Health Services, Inc., the nation's largest home healthcare company with a specialty in skilled nursing, physical therapy, occupational therapy and speech pathology within the Medicare population. Over his tenure there, he led the sales and marketing effort and was instrumental in the company achieving overall net revenue growth of 35% and same store sales growth of over 25%. Prior to Gentiva, Mr. Russo was Regional Vice President of Sales at Concentra, Inc., one of the largest providers of health care services in the nation, serving patients at 234 medical centers in 40 states. In his role at Concentra, Mr. Russo was responsible for both national and regional sales and marketing. During his tenure at the company, revenue increased from $250 million to over $1.2 billion. Mr. Russo holds a BS/BA degree in Business from
Mr. Steve Watkins, Chief Executive Officer, commented, "Bryan's proven ability to build relationships, implement effective marketing initiatives and drive sales in the home healthcare arena make him a valuable addition to our team. We welcome Bryan on board and look forward to his contributions to gain deeper and broader penetration of our ambulatory infusion pumps and associated clinical services within the oncology market."
About InfuSystem Holdings, Inc.
InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem's pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.
|SOURCE InfuSystem Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved